Long-term Aspirin Use Reduces Colon Cancer Risk, Study Shows

Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

BOSTON--Aspirin appears to reduce the risk of colorectal cancer in women, but only if taken regularly for 10 years or more, report Edward Giovannucci, MD, and his colleagues from Harvard Medical School.

BOSTON--Aspirin appears to reduce the risk of colorectal cancerin women, but only if taken regularly for 10 years or more, reportEdward Giovannucci, MD, and his colleagues from Harvard MedicalSchool.

Their findings, based on analysis of data from the Nurses' HealthStudy (a large cohort of women followed since 1976), suggest thatintervention trials may require long follow-up to show beneficialeffects of aspirin. A previous intervention trial using low-doseaspirin saw no reduction in colorectal cancers during the first6 years of follow-up (J Natl Cancer Inst 85:1220-1224, 1993).

Reduction Seen at 10 Years

Patterns of aspirin use were determined in the Nurses' Study cohortin three consecutive questionnaires (1980, 1982, and 1984), andcases of colorectal cancer occurring from 1984 through 1992 wereincluded (331 new cases during more than 500,000 person-yearsof follow-up).

"We found little reduction in the risk of colorectal cancerduring the first 9 years of regular aspirin use (relative risk,0.97), as compared with the risk among nonusers, but for 10 ormore years of use, the relative risk was 0.63," Dr. Giovannuccisaid in his New England Journal of Medicine report (333:609-614,1995).

The risk reduction was not significant among the 10- to 19-yearaspirin users but rose to clear significance among women who hadused aspirin regularly for at least 20 years (44% risk reduction).The full reduction in colorectal cancer risk occurred at a levelof four to six aspirin tablets a week, with no further benefitseen with increased doses.

Dr. Giovannucci noted that controlling for risk factors for colorectalcancer, including diet, family history, smoking, weight, physicalactivity, and alcohol consumption, did not alter the results.In addition, despite a slightly higher rate of endoscopy, womenwho took aspirin had fewer adenomas removed and fewer large adenomas.

The researchers suggest that risk reductions appear slowly overtime because aspirin may exert its preventive effects only atthe earliest stage of the disease (small adenomas).

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content